Identification
NameCelecoxib
Accession NumberDB00482  (APRD00373)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Structure
Thumb
Synonyms
Celebrex
Celecoxib
Célécoxib
Celecoxibum
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
External IDs SC 58635 / YM 177
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-celecoxibCapsule200 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-celecoxibCapsule100 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Act CelecoxibCapsule200 mgOralActavis Pharma Company2014-11-21Not applicableCanada
Act CelecoxibCapsule100 mgOralActavis Pharma Company2014-11-21Not applicableCanada
Ag-celecoxibCapsule100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-celecoxibCapsule200 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-celecoxibCapsule100 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-celecoxibCapsule200 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Bio-celecoxibCapsule100 mgOralBiomed Pharma2014-12-05Not applicableCanada
Bio-celecoxibCapsule200 mgOralBiomed Pharma2014-12-05Not applicableCanada
CelebrexCapsule100 mg/1OralA S Medication Solutions1999-01-252017-06-20Us
CelebrexCapsule100 mg/1OralCardinal Health1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralRebel Distributors1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralRemedy Repack2013-02-202016-10-26Us
CelebrexCapsule100 mg/1OralPd Rx Pharmaceuticals, Inc.1998-10-02Not applicableUs00025 1520 31 nlmimage10 5b39adcd
CelebrexCapsule200 mg/1OralAphena Pharma Solutions Tennessee, Inc.1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc1998-10-022017-04-15Us
CelebrexCapsule200 mg/1Oralbryant ranch prepack1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralKeltman Pharmaceuticals Inc.2006-03-01Not applicableUs
CelebrexCapsule100 mg/1OralPhysicians Total Care, Inc.1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralPd Rx Pharmaceuticals, Inc.1998-10-02Not applicableUs
CelebrexCapsule100 mg/1OralStat Rx USA1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralStat Rx USA1998-10-02Not applicableUs
CelebrexCapsule50 mg/1OralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
CelebrexCapsule100 mg/1Oralbryant ranch prepack1998-10-02Not applicableUs
CelebrexCapsule100 mgOralPfizer1999-04-19Not applicableCanada
CelebrexCapsule200 mg/1OralA S Medication Solutions1999-01-252017-06-20Us
CelebrexCapsule200 mg/1OralCardinal Health1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralAidarex Pharmaceuticals LLC1998-10-02Not applicableUs
CelebrexCapsule400 mg/1OralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralDirectrx2014-01-01Not applicableUs
CelebrexCapsule100 mg/1OralUnit Dose Services1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralClinical Solutions Wholsesale1998-10-022017-06-24Us
CelebrexCapsule200 mg/1OralUnit Dose Services1998-10-02Not applicableUs00025 1525 31 nlmimage10 5b39adfd
CelebrexCapsule200 mg/1OralH.J. Harkins Company1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2014-08-20Not applicableUs
CelebrexCapsule100 mg/1OralRebel Distributors1998-10-02Not applicableUs
CelebrexCapsule100 mg/1OralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs
CelebrexCapsule400 mg/1Oralbryant ranch prepack1998-10-022017-06-20Us
CelebrexCapsule200 mg/1Oralbryant ranch prepack1998-10-02Not applicableUs
CelebrexCapsule200 mgOralPfizer1999-04-19Not applicableCanada
CelebrexCapsule100 mg/1OralDispensing Solutions, Inc.1998-10-02Not applicableUs
CelebrexCapsule100 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-11-22Not applicableUs
CelebrexCapsule200 mg/1OralPhysicians Total Care, Inc.1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralCardinal Health1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralStat Rx USA1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralProficient Rx LP1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralA S Medication Solutions1998-10-022017-06-20Us
CelebrexCapsule100 mg/1OralH.J. Harkins Company1998-10-02Not applicableUs
CelebrexCapsule100 mg/1OralStat Rx USA1998-10-02Not applicableUs
CelecoxibCapsule50 mg/1OralMylan Pharmaceuticals2014-12-102016-10-13Us
CelecoxibCapsule400 mg/1OralMylan Pharmaceuticals2014-12-102017-08-31Us
CelecoxibCapsule100 mg/1OralPreferreed Pharmaceuticals Inc.2015-10-06Not applicableUs
CelecoxibCapsule100 mgOralSanis Health Inc2015-02-05Not applicableCanada
CelecoxibCapsule400 mg/1OralLupin Pharmaceuticals2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralAvera Mc Kennan Hospital2015-05-01Not applicableUs
CelecoxibCapsule200 mg/1Oralbryant ranch prepack2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralPd Rx Pharmaceuticals, Inc.2014-12-10Not applicableUs
CelecoxibCapsule50 mg/1OralLupin Pharmaceuticals2014-12-102016-11-18Us
CelecoxibCapsule200 mg/1OralMylan Pharmaceuticals2014-12-102018-03-31Us
CelecoxibCapsule200 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2014-12-102018-04-30Us
CelecoxibCapsule200 mg/1OralBlenheim Pharmcal, Inc2015-05-27Not applicableUs
CelecoxibCapsule100 mg/1OralUnit Dose Services2014-12-10Not applicableUs
CelecoxibCapsule400 mg/1OralActavis Pharma Company2014-12-102017-08-31Us
CelecoxibCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2015-04-20Not applicableUs00591 2825 01 nlmimage10 743fba2d
CelecoxibCapsule200 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
CelecoxibCapsule50 mg/1OralGreenstone, Llc2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralAphena Pharma Solutions Tennessee, Inc.2014-12-10Not applicableUs
CelecoxibCapsule400 mg/1OralGreenstone, Llc2014-12-10Not applicableUs
CelecoxibCapsule100 mg/1OralAidarex Pharmaceuticals LLC2014-12-10Not applicableUs00591 2820 01 nlmimage10 743fba5d
CelecoxibCapsule100 mgOralPro Doc Limitee2014-11-21Not applicableCanada
CelecoxibCapsule50 mg/1OralActavis Pharma Company2014-12-102016-10-13Us
CelecoxibCapsule100 mg/1OralActavis Pharma Company2014-12-102018-05-31Us
CelecoxibCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2014-12-22Not applicableUs
CelecoxibCapsule200 mgOralSanis Health Inc2015-02-05Not applicableCanada
CelecoxibCapsule100 mgOralSivem Pharmaceuticals Ulc2014-11-17Not applicableCanada
CelecoxibCapsule200 mg/1OralBlenheim Pharmacal, Inc.2016-02-12Not applicableUs
CelecoxibCapsule100 mg/1Oralbryant ranch prepack2014-12-10Not applicableUs
CelecoxibCapsule100 mg/1OralPd Rx Pharmaceuticals, Inc.2014-12-10Not applicableUs
CelecoxibCapsule100 mg/1OralLupin Pharmaceuticals2014-12-102016-11-18Us
CelecoxibCapsule200 mg/1OralDirectrx2015-01-01Not applicableUs
CelecoxibCapsule100 mg/1OralGreenstone, Llc2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralBlenheim Pharmacal, Inc.2015-07-20Not applicableUs
CelecoxibCapsule100 mgOralRanbaxy Inc.Not applicableNot applicableCanada
CelecoxibCapsule100 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
CelecoxibCapsule100 mg/1OralDirectrx2014-01-01Not applicableUs
CelecoxibCapsule200 mg/1OralAidarex Pharmaceuticals LLC2014-12-10Not applicableUs
CelecoxibCapsule100 mg/1OralMylan Pharmaceuticals2014-12-102017-08-31Us
CelecoxibCapsule100 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2014-12-102018-05-31Us
CelecoxibCapsule200 mg/1OralMesource Pharmaceuticals2014-12-10Not applicableUs68180 0598 01 nlmimage10 783fbc6d
CelecoxibCapsule200 mg/1OralLupin Pharmaceuticals2014-12-102016-11-18Us
CelecoxibCapsule200 mgOralPro Doc Limitee2014-11-21Not applicableCanada
CelecoxibCapsule200 mg/1OralBlenheim Pharmacal, Inc.2015-05-19Not applicableUs
CelecoxibCapsule200 mg/1OralUnit Dose Services2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralActavis Pharma Company2014-12-102018-04-30Us
CelecoxibCapsule100 mg/1OralPreferreed Pharmaceuticals Inc.2014-12-22Not applicableUs
CelecoxibCapsule100 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
CelecoxibCapsule200 mgOralSivem Pharmaceuticals Ulc2014-11-17Not applicableCanada
CelecoxibCapsule200 mgOralRanbaxy Inc.Not applicableNot applicableCanada
CelecoxibCapsule200 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
CelecoxibCapsule200 mg/1OralRemedy Repack2015-01-222017-03-11Us
CelecoxibCapsule200 mg/1OralGreenstone, Llc2014-12-10Not applicableUs59762 1517 01 nlmimage10 433da1ed
CelecoxibCapsule100 mg/1OralAvera Mc Kennan Hospital2015-10-02Not applicableUs
Dom-celecoxibCapsule200 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-celecoxibCapsule100 mgOralDominion PharmacalNot applicableNot applicableCanada
Gd-celecoxibCapsule200 mgOralGenmed A Division Of Pfizer Canada Inc2014-11-20Not applicableCanada
Gd-celecoxibCapsule100 mgOralGenmed A Division Of Pfizer Canada Inc2014-11-20Not applicableCanada
Ipg-celecoxibCapsule100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-celecoxibCapsule200 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-celecoxibCapsule100 mgOralJamp Pharma Corporation2014-11-27Not applicableCanada
Jamp-celecoxibCapsule200 mgOralJamp Pharma Corporation2014-11-27Not applicableCanada
Lupin-celecoxibCapsule100 mgOralLupin PharmaNot applicableNot applicableCanada
Lupin-celecoxibCapsule200 mgOralLupin PharmaNot applicableNot applicableCanada
Mar-celecoxibCapsule100 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-celecoxibCapsule200 mgOralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mint-celecoxibCapsule100 mgOralMint Pharmaceuticals Inc2014-11-17Not applicableCanada
Mint-celecoxibCapsule200 mgOralMint Pharmaceuticals Inc2014-11-17Not applicableCanada
Mylan-celecoxibCapsule100 mgOralMylan Pharmaceuticals2014-11-17Not applicableCanada
Mylan-celecoxibCapsule200 mgOralMylan Pharmaceuticals2014-11-17Not applicableCanada
PMS-celecoxibCapsule200 mgOralPharmascience Inc2014-11-17Not applicableCanada
PMS-celecoxibCapsule100 mgOralPharmascience Inc2014-11-17Not applicableCanada
Priva-celecoxibCapsule100 mgOralPharmapar Inc2014-12-31Not applicableCanada
Priva-celecoxibCapsule200 mgOralPharmapar Inc2014-12-31Not applicableCanada
Ran-celecoxibCapsule100 mgOralRanbaxy Inc.2014-11-17Not applicableCanada
Ran-celecoxibCapsule200 mgOralRanbaxy Inc.2014-11-17Not applicableCanada
Rbx-celecoxibCapsule200 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Rbx-celecoxibCapsule100 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Riva-celecoxCapsule100 mgOralLaboratoire Riva Inc2014-11-17Not applicableCanada
Riva-celecoxCapsule200 mgOralLaboratoire Riva Inc2014-11-17Not applicableCanada
Riva-celecoxibCapsule100 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-celecoxibCapsule200 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz CelecoxibCapsule100 mgOralSandoz Canada Incorporated2014-11-17Not applicableCanada
Sandoz CelecoxibCapsule200 mgOralSandoz Canada Incorporated2014-11-17Not applicableCanada
Sdz CelecoxibCapsule100 mgOralSandoz Canada Incorporated2016-05-15Not applicableCanada
Sdz CelecoxibCapsule200 mgOralSandoz Canada Incorporated2016-05-15Not applicableCanada
Teva-celecoxibCapsule100 mgOralTeva2014-11-17Not applicableCanada
Teva-celecoxibCapsule200 mgOralTeva2014-11-17Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-celecoxibCapsule200 mgOralApotex Corporation2014-11-17Not applicableCanada
Apo-celecoxibCapsule100 mgOralApotex Corporation2014-11-17Not applicableCanada
CelecoxibCapsule50 mg/1OralAurobindo Pharma2016-02-01Not applicableUs
CelecoxibCapsule200 mg/1OralPd Rx Pharmaceuticals, Inc.2015-09-23Not applicableUs69097 0421 07 nlmimage10 954d4aba
CelecoxibCapsule200 mg/1OralProficient Rx LP2015-06-03Not applicableUs
CelecoxibCapsule50 mg/1OralLupin Pharmaceuticals2015-08-07Not applicableUs
CelecoxibCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2016-08-16Not applicableUs
CelecoxibCapsule200 mg/1OralCardinal Health2015-06-25Not applicableUs
CelecoxibCapsule200 mg/1OralDenton Pharma, Inc.2017-03-16Not applicableUs
CelecoxibCapsule50 mg/1OralMacleods Pharmaceuticals Limited2016-03-16Not applicableUs
CelecoxibCapsule200 mg/1OralBlenheim Pharmacal, Inc.2015-11-05Not applicableUs
CelecoxibCapsule200 mg/1OralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
CelecoxibCapsule200 mg/1OralRemedy Repack2016-05-27Not applicableUs
CelecoxibCapsule100 mg/1OralActavis Pharma Company2015-03-12Not applicableUs
CelecoxibCapsule200 mg/1OralJubilant Cadista Pharmaceuticals Inc.2017-04-04Not applicableUs
CelecoxibCapsule200 mg/1OralMylan Institutional2015-02-24Not applicableUs
CelecoxibCapsule400 mg/1OralMylan Pharmaceuticals2015-04-15Not applicableUs
CelecoxibCapsule100 mg/1OralMajor2015-06-25Not applicableUs
CelecoxibCapsule400 mg/1OralTrigen Laboratories, Inc.2015-08-22Not applicableUs
CelecoxibCapsule100 mg/1OralCardinal Health2015-06-25Not applicableUs
CelecoxibCapsule100 mg/1OralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
CelecoxibCapsule200 mg/1OralTrigen Laboratories, Inc.2015-08-22Not applicableUs
CelecoxibCapsule100 mg/1OralAv Kare, Inc.2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralApotex Corporation2015-06-03Not applicableUs
CelecoxibCapsule400 mg/1OralAurobindo Pharma2016-02-01Not applicableUs
CelecoxibCapsule200 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-03-12Not applicableUs
CelecoxibCapsule400 mg/1OralLupin Pharmaceuticals2015-08-07Not applicableUs
CelecoxibCapsule200 mg/1OralA S Medication Solutions2016-02-012017-06-20Us
CelecoxibCapsule200 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-23Not applicableUs
CelecoxibCapsule200 mg/1OralRed Pharm Drug, Inc.2015-09-23Not applicableUs
CelecoxibCapsule400 mg/1OralMacleods Pharmaceuticals Limited2016-03-16Not applicableUs
CelecoxibCapsule400 mg/1OralTeva2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2016-05-23Not applicableUs
CelecoxibCapsule200 mg/1OralRxchange Co2015-06-03Not applicableUs
CelecoxibCapsule100 mg/1OralCipla Limited2015-09-23Not applicableUs
CelecoxibCapsule200 mg/1OralGolden State Medical Supply2015-11-09Not applicableUs
CelecoxibCapsule200 mg/1OralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
CelecoxibCapsule200 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2016-02-01Not applicableUs
CelecoxibCapsule50 mg/1OralJubilant Cadista Pharmaceuticals Inc.2017-04-04Not applicableUs
CelecoxibCapsule200 mg/1OralCambridge Therapeutics Technologies, Llc2016-02-01Not applicableUs
CelecoxibCapsule100 mg/1OralMylan Pharmaceuticals2015-04-15Not applicableUs
CelecoxibCapsule200 mg/1OralSt. Marys Medical Park Pharmacy2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralAlembic Pharmaceuticals Limited2015-12-01Not applicableUs
CelecoxibCapsule100 mg/1OralAurobindo Pharma2016-02-01Not applicableUs
CelecoxibCapsule200 mg/1OralA S Medication Solutions2014-12-102017-06-20Us
CelecoxibCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2016-01-042016-01-07Us
CelecoxibCapsule100 mg/1OralLupin Pharmaceuticals2015-08-07Not applicableUs
CelecoxibCapsule200 mg/1OralRemedy Repack2016-10-14Not applicableUs
CelecoxibCapsule100 mg/1OralNucare Pharmaceuticals, Inc.2015-06-03Not applicableUs
CelecoxibCapsule100 mg/1OralAmerincan Health Packaging2015-02-01Not applicableUs00093 7165 01 nlmimage10 c042e077
CelecoxibCapsule100 mg/1OralMacleods Pharmaceuticals Limited2016-03-16Not applicableUs
CelecoxibCapsule100 mg/1OralTeva2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralRemedy Repack2016-07-18Not applicableUs60505 3849 05 nlmimage10 7f4abfe5
CelecoxibCapsule200 mg/1OralPd Rx Pharmaceuticals, Inc.2014-12-10Not applicableUs
CelecoxibCapsule200 mg/1OralActavis Pharma Company2015-03-12Not applicableUs
CelecoxibCapsule400 mg/1OralJubilant Cadista Pharmaceuticals Inc.2017-04-04Not applicableUs
CelecoxibCapsule50 mg/1OralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
CelecoxibCapsule50 mg/1OralTrigen Laboratories, Inc.2015-08-22Not applicableUs
CelecoxibCapsule200 mg/1OralMajor2015-06-25Not applicableUs
CelecoxibCapsule50 mg/1OralApotex Corporation2015-06-03Not applicableUs
CelecoxibCapsule50 mg/1OralTeva2014-12-10Not applicableUs00093 7306 06 nlmimage10 bc42de66
CelecoxibCapsule200 mg/1OralAv Kare, Inc.2014-12-10Not applicableUs
CelecoxibCapsule50 mg/1OralAlembic Pharmaceuticals Limited2015-12-01Not applicableUs
CelecoxibCapsule400 mg/1OralCipla Limited2015-09-23Not applicableUs
CelecoxibCapsule50 mg/1OralGolden State Medical Supply2015-11-09Not applicableUs
CelecoxibCapsule50 mg/1OralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
CelecoxibCapsule200 mg/1OralA S Medication Solutions2015-09-232017-06-20Us
CelecoxibCapsule200 mg/1OralDirectrx2016-03-02Not applicableUs
CelecoxibCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2015-10-15Not applicableUs
CelecoxibCapsule50 mg/1OralCipla Limited2015-09-23Not applicableUs
CelecoxibCapsule400 mg/1OralGolden State Medical Supply2015-11-09Not applicableUs
CelecoxibCapsule400 mg/1OralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
CelecoxibCapsule50 mg/1OralActavis Pharma Company2015-03-12Not applicableUs
CelecoxibCapsule100 mg/1OralJubilant Cadista Pharmaceuticals Inc.2017-04-04Not applicableUs
CelecoxibCapsule100 mg/1OralMylan Institutional2015-02-24Not applicableUs
CelecoxibCapsule50 mg/1OralMylan Pharmaceuticals2015-04-15Not applicableUs
CelecoxibCapsule100 mg/1OralProficient Rx LP2014-12-10Not applicableUs
CelecoxibCapsule400 mg/1OralAlembic Pharmaceuticals Limited2015-12-01Not applicableUs
CelecoxibCapsule400 mg/1OralTorrent Pharmaceuticals Limited2015-12-23Not applicableUs
CelecoxibCapsule100 mg/1OralTrigen Laboratories, Inc.2015-08-22Not applicableUs
CelecoxibCapsule50 mg/1OralAv Kare, Inc.2014-12-10Not applicableUs
CelecoxibCapsule100 mg/1OralApotex Corporation2015-06-03Not applicableUs60505 3848 01 nlmimage10 37489ba4
CelecoxibCapsule200 mg/1OralAurobindo Pharma2016-02-01Not applicableUs
CelecoxibCapsule200 mg/1OralUnit Dose Services2015-03-12Not applicableUs
CelecoxibCapsule200 mg/1OralLupin Pharmaceuticals2015-08-07Not applicableUs
CelecoxibCapsule200 mg/1OralA S Medication Solutions2015-03-122017-06-20Us
CelecoxibCapsule100 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2015-09-23Not applicableUs
CelecoxibCapsule200 mg/1OralAmerincan Health Packaging2015-02-01Not applicableUs00093 7166 01 nlmimage10 c142e0a7
CelecoxibCapsule200 mg/1OralMacleods Pharmaceuticals Limited2016-03-16Not applicableUs
CelecoxibCapsule200 mg/1OralTeva2014-12-10Not applicableUs
CelecoxibCapsule100 mg/1OralProficient Rx LP2015-09-23Not applicableUs
CelecoxibCapsule100 mg/1OralProficient Rx LP2015-03-12Not applicableUs
CelecoxibCapsule400 mg/1OralActavis Pharma Company2015-03-12Not applicableUs
CelecoxibCapsule100 mg/1OralPreferreed Pharmaceuticals Inc.2017-04-05Not applicableUs
CelecoxibCapsule100 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2016-02-01Not applicableUs
CelecoxibCapsule200 mg/1OralMylan Pharmaceuticals2015-04-15Not applicableUs
CelecoxibCapsule400 mg/1OralAv Kare, Inc.2014-12-10Not applicableUs00093 7170 06 nlmimage10 c542e2b7
CelecoxibCapsule100 mg/1OralAlembic Pharmaceuticals Limited2015-12-01Not applicableUs
CelecoxibCapsule200 mg/1OralCipla Limited2015-09-23Not applicableUs
CelecoxibCapsule100 mg/1OralGolden State Medical Supply2015-11-09Not applicableUs
CelecoxibCapsule100 mg/1OralAlembic Pharmaceuticals Limited2015-08-22Not applicableUs
Celecoxib 100 mgCapsule100 mg/1OralSydon Labs Llc2015-11-24Not applicableUs
Celecoxib 200 mgCapsule200 mg/1OralSydon Labs Llc2015-11-24Not applicableUs
Celecoxib 200 mgCapsule200 mg/1OralProficient Rx LP2015-11-24Not applicableUs
Celecoxib 200 mgCapsule200 mg/1OralSydon Labs Llc2017-03-17Not applicableUs
Celecoxib 200 mgCapsule200 mg/1OralAidarex Pharmaceuticals LLC2015-11-24Not applicableUs
Celecoxib 200 mgCapsule200 mg/1OralPreferreed Pharmaceuticals Inc.2016-01-08Not applicableUs
Celecoxib 400 mgCapsule400 mg/1OralSydon Labs Llc2015-11-24Not applicableUs
Celecoxib 50 mgCapsule50 mg/1OralSydon Labs Llc2015-11-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OnsenalCapsule200 mgOralPfizer2003-10-17Not applicableEu
OnsenalCapsule200 mgOralPfizer2003-10-17Not applicableEu
OnsenalCapsule200 mgOralPfizer2003-10-17Not applicableEu
OnsenalCapsule400 mgOralPfizer2003-10-17Not applicableEu
OnsenalCapsule200 mgOralPfizer2003-10-17Not applicableEu
OnsenalCapsule400 mgOralPfizer2003-10-17Not applicableEu
International Brands
NameCompany
ArticoxKeyfarm
ArticoxibNabiqasim
ArtiflexStandpharm
ArtilogPfizer
ArtixPharmalab
ArtrixibIntipharma
BlocktenInfarmasa
CaditarFarmindustria
CefinixFarmacoop
CelactSun
CelebraPfizer
OnsenalPfizer
ValdynePfizer
Brand mixtures
NameLabellerIngredients
CapxibMas Management Group
Categories
UNIIJCX84Q7J1L
CAS number169590-42-5
WeightAverage: 381.372
Monoisotopic: 381.075882012
Chemical FormulaC17H14F3N3O2S
InChI KeyRZEKVGVHFLEQIL-UHFFFAOYSA-N
InChI
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
IUPAC Name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
SMILES
CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Pharmacology
Indication

For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis

Structured Indications
Pharmacodynamics

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Because of its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of celecoxib on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of celecoxib. Inhibition of PGE2 synthesis may lead to sodium and water retention through increased fluid reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit water reabsorption by counteracting the action of antidiuretic hormone.

Mechanism of action

The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis. Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site. Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane.

TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
3-phosphoinositide-dependent protein kinase 1Proteinunknown
inhibitor
HumanO15530 details
Carbonic anhydrase 2Proteinunknown
inhibitor
HumanP00918 details
Carbonic anhydrase 3Proteinunknown
inhibitor
HumanP07451 details
Related Articles
Absorption

Well absorbed in the gastrointestinal tract. When a single dose of 200 mg is given to healthy subjects, peak plasma levels occur 3 hours after an oral dose. The peak plasma level is 705 ng/mL. Absolute bioavailability studies have not been conducted. When multiple doses are given, steady-state is reached on or before Day 5. When taken with a high fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%.

Volume of distribution

Apparent volume of distribution at steady state (Vdss/F), 200 mg single dose, healthy subjects = 429 L

Protein binding

97%, primarily to albumin and, to a lesser extent, a1-acid glycoprotein. Celecoxib is not preferentially bound to red blood cells.

Metabolism

Hepatic. Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. CYP3A4 is also involved in the hydroxylation of celecoxib but to a lesser extent. These metabolites are inactive as COX-1 or COX-2 inhibitors.

SubstrateEnzymesProduct
Celecoxib
HydroxycelecoxibDetails
Hydroxycelecoxib
CarboxycelecoxibDetails
Carboxycelecoxib
Celecoxib glucuronideDetails
Route of elimination

Celecoxib is eliminated predominantly by hepatic metabolism with little (<3%) unchanged drug recovered in the urine and feces. 57% of the oral dose is excreted in the feces and 27% is excreted into the urine. The primary metabolite in urine and feces was the carboxylic acid metabolite (73%). The amount of glucuronide in the urine is low.

Half life

The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption.

Clearance

Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr.

Toxicity

Symptoms of overdose include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Celecoxib Action PathwayDrug actionSMP00096
Celecoxib Metabolism PathwayDrug metabolismSMP00644
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C Allele Effect Directly StudiedPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*6Not Available818delA Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*15Not Available485C>A Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAA Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*2Not Available430C>T Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*4Not Available1076T>C Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*5Not Available1080C>G Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*8Not Available449G>A Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*11Not Available1003C>T Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*12Not Available1465C>T Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*13Not Available269T>C Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*14Not Available374G>A Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*16Not Available895A>G Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*33Not Available395G>A Effect InferredPoor drug metabolizer, lower dose requirements Details
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Celecoxib.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabCelecoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Celecoxib can be decreased when combined with Abiraterone.Approved
AcebutololCelecoxib may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Celecoxib.Approved
AcenocoumarolCelecoxib may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Celecoxib.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Celecoxib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Celecoxib.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Celecoxib.Approved, Vet Approved
AclarubicinCelecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Celecoxib.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Celecoxib.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.Approved
AliskirenCelecoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Celecoxib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Celecoxib.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Celecoxib.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Celecoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Amcinonide.Approved
AmikacinCelecoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideCelecoxib may decrease the antihypertensive activities of Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Celecoxib.Approved, Withdrawn
AmiodaroneThe metabolism of Celecoxib can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Celecoxib.Approved
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Celecoxib.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Celecoxib.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Celecoxib.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Celecoxib.Approved
AmrubicinCelecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Celecoxib.Approved
AncrodCelecoxib may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Celecoxib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Celecoxib is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Celecoxib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Celecoxib.Approved
Antithrombin III humanCelecoxib may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCelecoxib may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Celecoxib.Investigational
ApramycinCelecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Celecoxib.Approved, Investigational
AprepitantThe serum concentration of Celecoxib can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Celecoxib.Approved
ArbekacinCelecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinCelecoxib may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Celecoxib.Approved, Investigational
ArgatrobanCelecoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
ArotinololCelecoxib may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe metabolism of Artemether can be decreased when combined with Celecoxib.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Celecoxib.Approved, Withdrawn
AtazanavirThe metabolism of Celecoxib can be decreased when combined with Atazanavir.Approved, Investigational
AtenololCelecoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Celecoxib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Celecoxib.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Celecoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Celecoxib.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Celecoxib.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Celecoxib.Approved, Investigational
BazedoxifeneCelecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminCelecoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCelecoxib may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Celecoxib.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Celecoxib.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Celecoxib.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Celecoxib.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Celecoxib.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Celecoxib.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Celecoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Celecoxib.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Celecoxib.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
BevantololCelecoxib may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Celecoxib can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Celecoxib.Approved
BivalirudinCelecoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Celecoxib can be decreased when combined with Boceprevir.Withdrawn
BopindololCelecoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Celecoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Celecoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Celecoxib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Celecoxib.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Celecoxib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Celecoxib.Investigational
BucindololCelecoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Budesonide.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Celecoxib.Experimental, Investigational
BumetanideCelecoxib may decrease the diuretic activities of Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Celecoxib.Approved, Investigational
BupranololCelecoxib may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Celecoxib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Celecoxib.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Celecoxib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Celecoxib.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Celecoxib.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Celecoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Celecoxib.Experimental
CapecitabineThe metabolism of Celecoxib can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Celecoxib.Approved
CarbamazepineThe metabolism of Celecoxib can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Celecoxib.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Celecoxib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Celecoxib.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Celecoxib.Approved, Vet Approved, Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Celecoxib.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Celecoxib.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Celecoxib.Experimental
CeliprololCelecoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Celecoxib.Approved, Vet Approved
CeritinibThe serum concentration of Celecoxib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Celecoxib.Withdrawn
CertoparinCelecoxib may increase the anticoagulant activities of Certoparin.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Celecoxib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Celecoxib.Approved, Illicit
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Celecoxib.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
ChlorotrianiseneCelecoxib may increase the thrombogenic activities of Chlorotrianisene.Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Celecoxib.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Celecoxib.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Celecoxib.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Celecoxib.Approved
CholecalciferolThe metabolism of Celecoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Celecoxib.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Celecoxib.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Celecoxib.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Celecoxib.Approved
CinoxacinCelecoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinCelecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the antiplatelet activities of Celecoxib.Approved
Citric AcidCelecoxib may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Celecoxib can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Celecoxib can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Celecoxib.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clodronate.Approved, Investigational, Vet Approved
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Celecoxib.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Celecoxib.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Celecoxib.Approved
ClotrimazoleThe metabolism of Celecoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Celecoxib.Approved
CobicistatThe metabolism of Celecoxib can be decreased when combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Celecoxib.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Celecoxib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensCelecoxib may increase the thrombogenic activities of Conjugated Equine Estrogens.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Celecoxib can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Celecoxib.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
CyclosporineCelecoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Celecoxib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateCelecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib.Approved
DalteparinCelecoxib may increase the anticoagulant activities of Dalteparin.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Celecoxib.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Celecoxib.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Celecoxib.Approved, Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Celecoxib.Approved, Investigational
DarexabanCelecoxib may increase the anticoagulant activities of Ym150.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Celecoxib.Approved, Investigational
DarunavirThe metabolism of Celecoxib can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Celecoxib.Approved
DasatinibThe serum concentration of Celecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinCelecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Celecoxib.Approved
DeferasiroxThe serum concentration of Celecoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Celecoxib can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Celecoxib.Approved
DesirudinCelecoxib may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Celecoxib.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoximetasone.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Celecoxib.Approved
DexamethasoneThe serum concentration of Celecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Celecoxib.Approved, Illicit, Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Celecoxib.Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Celecoxib.Approved
DextranCelecoxib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Celecoxib may increase the anticoagulant activities of Dextran 40.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Celecoxib.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Celecoxib.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Celecoxib.Approved, Illicit, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Celecoxib.Approved, Vet Approved
DicoumarolCelecoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolCelecoxib may increase the thrombogenic activities of Dienestrol.Approved
DiethylstilbestrolCelecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Celecoxib.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Celecoxib.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Celecoxib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Celecoxib.Approved, Illicit
DihydroergotamineThe metabolism of Celecoxib can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Celecoxib can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Celecoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Celecoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Celecoxib.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Celecoxib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Celecoxib.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Celecoxib.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Celecoxib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Celecoxib.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Celecoxib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Celecoxib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Celecoxib.Approved, Investigational
DoxorubicinCelecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Celecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Celecoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneCelecoxib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Celecoxib.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Celecoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Celecoxib.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with Celecoxib.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Celecoxib.Investigational
Edetic AcidCelecoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCelecoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Celecoxib can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Celecoxib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Celecoxib.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Celecoxib.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Celecoxib.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Celecoxib.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Celecoxib.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Celecoxib.Investigational
EnoxacinCelecoxib may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinCelecoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Celecoxib.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Celecoxib.Approved
EpirubicinCelecoxib may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneCelecoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Celecoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Celecoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Celecoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Equilin.Approved
EquolCelecoxib may increase the thrombogenic activities of S Equol.Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Celecoxib.Approved, Investigational
ErythromycinThe metabolism of Celecoxib can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Celecoxib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Celecoxib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Celecoxib.Investigational
EsmololCelecoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolCelecoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolCelecoxib may increase the thrombogenic activities of Estriol.Approved, Vet Approved
EstroneCelecoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Estrone sulfate.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Celecoxib.Approved
Etacrynic acidCelecoxib may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Celecoxib.Approved, Investigational
Ethinyl EstradiolCelecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateCelecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Celecoxib.Approved, Illicit
Etidronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Celecoxib.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Celecoxib.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Celecoxib can be decreased when it is combined with Etravirine.Approved
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Celecoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Celecoxib.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Celecoxib.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Celecoxib.Approved, Withdrawn
FleroxacinCelecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Celecoxib.Approved, Withdrawn
FloxuridineThe metabolism of Celecoxib can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Celecoxib can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fludrocortisone.Approved
FluindioneCelecoxib may increase the anticoagulant activities of Fluindione.Investigational
FlumequineCelecoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Celecoxib.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Celecoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Celecoxib.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Celecoxib.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluprednidene.Approved, Withdrawn
FlurandrenolideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Celecoxib.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Celecoxib.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Celecoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxCelecoxib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumCelecoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Celecoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be decreased when combined with Celecoxib.Approved, Investigational
FosamprenavirThe metabolism of Celecoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Celecoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Celecoxib.Approved
FosphenytoinThe metabolism of Celecoxib can be increased when combined with Fosphenytoin.Approved
FramycetinCelecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideCelecoxib may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Celecoxib can be increased when it is combined with Fusidic Acid.Approved
GabexateCelecoxib may increase the anticoagulant activities of Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Celecoxib.Approved
GatifloxacinCelecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Celecoxib.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Celecoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Celecoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinCelecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCelecoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinCelecoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinCelecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACelecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Celecoxib.Approved, Investigational
GrepafloxacinCelecoxib may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Celecoxib.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Celecoxib.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Celecoxib is combined with HE3286.Investigational
HeparinCelecoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolCelecoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Celecoxib.Investigational
HydralazineCelecoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Celecoxib.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Celecoxib.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Celecoxib.Approved, Illicit
IbandronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Celecoxib.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Celecoxib.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Celecoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Celecoxib.Approved
IdarubicinCelecoxib may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Celecoxib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Celecoxib.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Celecoxib.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Celecoxib.Approved, Investigational
ImatinibThe metabolism of Celecoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Celecoxib.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Celecoxib.Approved
IndalpineIndalpine may increase the antiplatelet activities of Celecoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.Approved
IndenololCelecoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Celecoxib can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Celecoxib.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Celecoxib.Approved
IrbesartanThe metabolism of Celecoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Celecoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Celecoxib.Withdrawn
IsradipineThe metabolism of Celecoxib can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Celecoxib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Celecoxib can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Celecoxib.Approved
KanamycinCelecoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Celecoxib.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Celecoxib.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Celecoxib.Approved
KetoconazoleThe metabolism of Celecoxib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Celecoxib.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Celecoxib.Approved
LabetalolThe metabolism of Labetalol can be decreased when combined with Celecoxib.Approved
LandiololCelecoxib may decrease the antihypertensive activities of Aop200704.Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Celecoxib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Celecoxib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Celecoxib.Approved, Investigational
LepirudinCelecoxib may increase the anticoagulant activities of Lepirudin.Approved
LevobunololCelecoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Celecoxib.Approved
LevofloxacinCelecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Celecoxib.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Celecoxib.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Celecoxib.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Celecoxib.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Celecoxib.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Celecoxib.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Celecoxib.Approved
LithiumThe serum concentration of Lithium can be increased when it is combined with Celecoxib.Approved
LomefloxacinCelecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Celecoxib.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Celecoxib.Approved
LopinavirThe metabolism of Celecoxib can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Celecoxib.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Celecoxib.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Celecoxib.Approved
LosartanThe metabolism of Celecoxib can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Celecoxib can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Celecoxib.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Celecoxib.Approved, Investigational
LuliconazoleThe serum concentration of Celecoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Celecoxib can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Celecoxib.Approved
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Celecoxib.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Celecoxib.Approved
ME-609The risk or severity of adverse effects can be increased when Celecoxib is combined with ME-609.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Celecoxib.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Celecoxib.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Celecoxib.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Celecoxib.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Celecoxib.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Celecoxib.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Celecoxib.Approved
MestranolCelecoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Celecoxib.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Celecoxib.Approved
MethallenestrilCelecoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Celecoxib.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Celecoxib.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Celecoxib.Approved, Vet Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Celecoxib.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Methylprednisolone.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Celecoxib.Approved, Illicit, Withdrawn
MetipranololCelecoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Celecoxib.Approved, Investigational
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Celecoxib.Approved, Investigational
MetrizamideCelecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Celecoxib.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Celecoxib.Approved
MifepristoneThe serum concentration of Celecoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Celecoxib.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Celecoxib.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Celecoxib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Celecoxib.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Celecoxib.Approved
MitotaneThe serum concentration of Celecoxib can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Celecoxib.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Celecoxib.Approved
ModafinilThe serum concentration of Celecoxib can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Celecoxib.Approved
MometasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Celecoxib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Celecoxib.Approved, Investigational
MoxifloxacinCelecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Celecoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Celecoxib.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Celecoxib.Approved
NadololCelecoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCelecoxib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Celecoxib.Approved, Investigational
NafcillinThe serum concentration of Celecoxib can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Celecoxib.Approved
Nalidixic AcidCelecoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Celecoxib.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Celecoxib.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Celecoxib.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Celecoxib is combined with NCX 1022.Investigational
NeamineCelecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Celecoxib.Approved, Investigational
NefazodoneThe metabolism of Celecoxib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Celecoxib can be decreased when combined with Nelfinavir.Approved
NeomycinCelecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Celecoxib.Approved
NetilmicinCelecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Celecoxib can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Celecoxib can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Celecoxib can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Celecoxib.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Celecoxib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Celecoxib.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Celecoxib.Approved
NilotinibThe metabolism of Celecoxib can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Celecoxib.Approved, Withdrawn
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Celecoxib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Celecoxib.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Celecoxib.Approved, Vet Approved
NorfloxacinCelecoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Celecoxib.Approved
OfloxacinCelecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Celecoxib.Approved, Investigational
OlaparibThe metabolism of Celecoxib can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Celecoxib.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Celecoxib.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Celecoxib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Celecoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Celecoxib.Investigational
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Celecoxib.Approved
OmeprazoleThe metabolism of Celecoxib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Celecoxib.Approved
OsimertinibThe serum concentration of Celecoxib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Celecoxib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Celecoxib.Approved
OxprenololCelecoxib may decrease the antihypertensive activities of Oxprenolol.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Celecoxib.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Celecoxib.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Celecoxib.Approved, Vet Approved
PalbociclibThe serum concentration of Celecoxib can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Celecoxib.Approved, Investigational
PamidronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pamidronate.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Celecoxib.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Parecoxib.Approved
ParomomycinCelecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Celecoxib.Approved
PazufloxacinCelecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCelecoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCelecoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Celecoxib.Approved
PentobarbitalThe metabolism of Celecoxib can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateCelecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Celecoxib.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Celecoxib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Celecoxib.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Celecoxib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Celecoxib.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Celecoxib.Approved, Withdrawn
PhenindioneCelecoxib may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Celecoxib can be increased when combined with Phenobarbital.Approved
PhenprocoumonCelecoxib may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Celecoxib.Approved, Vet Approved
PhenytoinThe metabolism of Celecoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Celecoxib.Approved, Investigational
PindololThe metabolism of Pindolol can be decreased when combined with Celecoxib.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Celecoxib.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Celecoxib.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Celecoxib.Approved
PirarubicinCelecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideCelecoxib may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Celecoxib.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Celecoxib.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Celecoxib.Approved
PlicamycinCelecoxib may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Celecoxib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Celecoxib.Approved
PosaconazoleThe metabolism of Celecoxib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololCelecoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Celecoxib.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Celecoxib is combined with dehydroepiandrosterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pregnenolone.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prilocaine.Approved
PrimidoneThe metabolism of Celecoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Celecoxib can be increased when it is combined with Probenecid.Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Celecoxib.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Celecoxib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Celecoxib.Approved, Vet Approved
PromestrieneCelecoxib may increase the thrombogenic activities of Promestriene.Investigational
PromethazineThe metabolism of Promethazine can be decreased when combined with Celecoxib.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Celecoxib.Approved
PropafenoneThe serum concentration of Celecoxib can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Celecoxib.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Celecoxib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Celecoxib.Experimental
Protein S humanCelecoxib may increase the anticoagulant activities of Protein S human.Approved
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Celecoxib.Approved
PrulifloxacinCelecoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Celecoxib.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Celecoxib.Investigational
PuromycinCelecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Celecoxib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Celecoxib.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Celecoxib.Approved, Investigational
QuinestrolCelecoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Celecoxib.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Celecoxib.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Celecoxib.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Celecoxib.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Celecoxib.Approved
RanolazineThe metabolism of Celecoxib can be decreased when combined with Ranolazine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Celecoxib.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Celecoxib.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Celecoxib.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Celecoxib.Experimental, Investigational
ReviparinCelecoxib may increase the anticoagulant activities of Reviparin.Approved
RibostamycinCelecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Celecoxib can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Celecoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Celecoxib can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rimexolone.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Celecoxib.Approved
RisedronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Risedronate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Celecoxib.Approved, Investigational
RitonavirThe metabolism of Celecoxib can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanCelecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rofecoxib.Investigational, Withdrawn
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Celecoxib.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Celecoxib.Approved, Investigational
RosoxacinCelecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Celecoxib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Celecoxib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Celecoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Celecoxib.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Celecoxib.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Celecoxib.Experimental
SaquinavirThe metabolism of Celecoxib can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Celecoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolCelecoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Celecoxib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Celecoxib.Approved, Withdrawn
SertralineSertraline may increase the antiplatelet activities of Celecoxib.Approved
SildenafilThe metabolism of Celecoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Celecoxib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Celecoxib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Celecoxib.Approved
SisomicinCelecoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Celecoxib.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sodium Nitrite.Approved
SorafenibThe metabolism of Celecoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolCelecoxib may decrease the antihypertensive activities of Sotalol.Approved
SP1049CCelecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinCelecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Celecoxib.Experimental
SpectinomycinCelecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Celecoxib.Approved
SpironolactoneCelecoxib may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Celecoxib.Investigational
St. John's WortThe serum concentration of Celecoxib can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Celecoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinCelecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinCelecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Celecoxib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Celecoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Celecoxib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Celecoxib.Approved
SulfisoxazoleThe metabolism of Celecoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Celecoxib.Approved
SulodexideCelecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Celecoxib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Celecoxib.Approved, Withdrawn
Synthetic Conjugated Estrogens, ACelecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BCelecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusCelecoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Celecoxib.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Celecoxib.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Celecoxib resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Celecoxib.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Celecoxib.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Celecoxib.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Celecoxib.Approved, Investigational
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Technetium Tc-99m Medronate.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Celecoxib.Investigational, Withdrawn
TelaprevirThe metabolism of Celecoxib can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Celecoxib can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Celecoxib.Approved, Investigational
TemafloxacinCelecoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Celecoxib.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Celecoxib.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Celecoxib.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Celecoxib.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Celecoxib.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Celecoxib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Celecoxib.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Celecoxib.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Celecoxib.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Celecoxib.Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Celecoxib.Approved
TiboloneCelecoxib may increase the thrombogenic activities of Tibolone.Approved
TicagrelorThe metabolism of Celecoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Celecoxib can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiludronate.Approved, Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Celecoxib.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Celecoxib.Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Celecoxib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Celecoxib.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tixocortol.Approved
TobramycinCelecoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Celecoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Celecoxib can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Celecoxib.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Celecoxib.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Celecoxib.Approved, Investigational
TorasemideCelecoxib may decrease the diuretic activities of Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Celecoxib.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Celecoxib.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Celecoxib.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Celecoxib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Celecoxib.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Celecoxib.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Celecoxib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Celecoxib.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCelecoxib may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Celecoxib.Approved
TrimethoprimThe metabolism of Celecoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Celecoxib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Celecoxib.Withdrawn
TrovafloxacinCelecoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Celecoxib.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Celecoxib.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Celecoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinCelecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Celecoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Celecoxib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Celecoxib.Approved
VerapamilThe metabolism of Celecoxib can be decreased when combined with Verapamil.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Celecoxib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Celecoxib.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Celecoxib.Approved, Investigational
VoriconazoleThe metabolism of Celecoxib can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Celecoxib.Approved
WarfarinCelecoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCelecoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
YohimbineThe metabolism of Yohimbine can be decreased when combined with Celecoxib.Approved, Vet Approved
ZafirlukastThe metabolism of Celecoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Celecoxib.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Celecoxib.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Celecoxib.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Celecoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Celecoxib.Withdrawn
ZiprasidoneThe metabolism of Celecoxib can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zoledronic acid.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Celecoxib.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Celecoxib.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Celecoxib.Approved
ZorubicinCelecoxib may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.Approved, Investigational
Food Interactions
  • Take without regard to meals.
  • Taking this product with a high-fat meal will delay the Cmax, but total absorption will be increased by 10 to 20%.
References
Synthesis ReferenceUS5466823
General References
  1. Malhotra S, Shafiq N, Pandhi P: COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed. 2004 Mar 23;6(1):6. [PubMed:15208519 ]
  2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. [PubMed:10979111 ]
  3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15. [PubMed:15713944 ]
  4. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford). 2007 Jan;46(1):135-40. Epub 2006 Jun 15. [PubMed:16777855 ]
  5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84. [PubMed:16943400 ]
  6. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423-9. [PubMed:12392591 ]
External Links
ATC CodesL01XX33 — CelecoxibM01AH01 — CelecoxibG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 28:08.04.08
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (102 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentStage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
0CompletedBasic ScienceBMI >30 kg/m21
0RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
0TerminatedBasic ScienceBone Ingrowth / Pain1
1Active Not RecruitingPreventionHead and Neck Carcinoma1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers7
1CompletedPreventionColorectal Cancers / Precancerous Conditions1
1CompletedPreventionMalignant Neoplasm of Prostate1
1CompletedTreatmentAdvanced Esophageal Cancers / Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Non-Small-Cell Lung Carcinoma (NSCLC) / Pleural Mesotheliomas / Primary Small Cell Lung Cancers1
1CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
1CompletedTreatmentColorectal Cancers / Diarrhea1
1CompletedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1CompletedTreatmentEsophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Sarcomas / Thymic Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHereditary Nonpolyposis / Neoplasms, Colorectal1
1CompletedTreatmentLung Cancers3
1CompletedTreatmentNeoplasms, Hepatic1
1CompletedTreatmentPain1
1CompletedTreatmentPostoperative pain1
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentStage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1CompletedTreatmentTuberculosis1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1CompletedTreatmentPainful musculoskeletal conditions1
1RecruitingNot AvailableHealthy Volunteers1
1RecruitingBasic ScienceElectrophysiologic Property of Brain1
1RecruitingTreatmentBladder Cancers1
1RecruitingTreatmentGlioblastomas1
1RecruitingTreatmentNeuroblastomas1
1SuspendedTreatmentGliomas1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1TerminatedTreatmentAdvanced thymic carcinoma / Esophageal Cancers / Lung Cancers / Mesolthelioma / Thoracic Sarcomas1
1TerminatedTreatmentHealthy Volunteers1
1TerminatedTreatmentInflammatory Reaction1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1Unknown StatusNot AvailableHealthy Male Volunteers1
1WithdrawnBasic ScienceNon-Small-Cell Lung Carcinoma (NSCLC)1
1WithdrawnTreatmentMelanoma / Neoplasms Metastasis / Neoplasms, Germ Cell and Embryonal / Sarcomas1
1, 2Active Not RecruitingPreventionBiomarker Change Linked to Breast Cancer1
1, 2Active Not RecruitingPreventionCancer, Breast1
1, 2Active Not RecruitingTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
1, 2CompletedBasic ScienceCardiovascular Disease (CVD) / Hypertensive / Obstructive Sleep Apnea (OSA) / Strokes1
1, 2CompletedBasic ScienceMouth Neoplasms1
1, 2CompletedPreventionTobacco Use Disorders1
1, 2CompletedTreatmentAdvanced Melanoma1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentCervical Cancers1
1, 2CompletedTreatmentCervix Neoplasms1
1, 2CompletedTreatmentLiver Cancer1
1, 2CompletedTreatmentLung Cancers2
1, 2CompletedTreatmentNasopharyngeal Carcinoma1
1, 2CompletedTreatmentNeoplasms, Colorectal1
1, 2RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface / Malignant Peritoneal Mesothelioma / Peritoneal Carcinomatosis1
1, 2SuspendedTreatmentEsophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Sarcomas / Thymic Carcinoma1
1, 2Unknown StatusTreatmentCancer of the Head / Cancer of the Larynx / Cancer of the Neck / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
1, 2Unknown StatusTreatmentHead and Neck Carcinoma1
1, 2WithdrawnTreatmentLiver Cancer1
2Active Not RecruitingPreventionCervical Cancers / Cervical Intraepithelial Neoplasia Grade 2 / Cervical Intraepithelial Neoplasia Grade 31
2Active Not RecruitingTreatmentEsophageal Cancers1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2Active Not RecruitingTreatmentFamilial Adenomatous Polyposis (FAP)1
2Active Not RecruitingTreatmentNeurofibromatosis 11
2CompletedNot AvailableMetastatic Hormone Refractory Prostate Cancer1
2CompletedDiagnosticNeoplasms1
2CompletedPreventionCancer, Breast2
2CompletedPreventionColorectal Cancers1
2CompletedPreventionEsophageal Cancers1
2CompletedPreventionHead and Neck Carcinoma1
2CompletedPreventionHead and Neck Carcinoma / Precancerous Conditions1
2CompletedPreventionLung Cancers2
2CompletedPreventionMonoclonal Gammopathy of Undetermined Significance (MGUS) / Multiple Myeloma (MM) / Smoldering Multiple Myeloma (SMM)1
2CompletedPreventionNo Evidence of Disease2
2CompletedPreventionNon-Melanomatous Skin Cancer1
2CompletedPreventionOral Mucositis1
2CompletedPreventionPrecancerous Conditions1
2CompletedSupportive CarePain1
2CompletedSupportive CareTonsillitis1
2CompletedTreatmentAdenotonsillectomy / Postoperative pain / Tonsillectomy1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnaplastic Glioma of Brain / Brain Cancer / Glioblastoma Multiforme1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentBrain Stem Gliomas1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCarcinoma, Colorectal / Colorectal Adenomas1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentColorectal Cancers4
2CompletedTreatmentDental Pain2
2CompletedTreatmentEsophageal Cancers2
2CompletedTreatmentFacial Pain1
2CompletedTreatmentGastric Carcinoma / Gastroesophageal Junction Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
2CompletedTreatmentLocally Advanced Rectal Cancer1
2CompletedTreatmentLung Cancers5
2CompletedTreatmentMacular Degeneration1
2CompletedTreatmentMalignant Neoplasm of Pancreas2
2CompletedTreatmentMalignant Neoplasm of Prostate1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon Muscle Invasive Bladder Cancer1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPain1
2CompletedTreatmentPain, Acute1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
2CompletedTreatmentRecurrent Respiratory Papillomatosis1
2CompletedTreatmentRenal Cell Adenocarcinoma / Stage IV Renal Cell Cancer1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSchizophrenic Disorders1
2CompletedTreatmentTemporomandibular Joint Disorders1
2CompletedTreatmentSynovitis of osteoarthritis1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
2Not Yet RecruitingTreatmentSpinal Muscular Atrophy (SMA)1
2RecruitingPreventionOral Squamous Cell Carcinoma1
2RecruitingPreventionPain, Neuropathic1
2RecruitingSupportive CareCancer of Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCarcinoma of Buccal Mucosa / Head and Neck Carcinoma / Oral Squamous Cell Carcinoma / Tongue Cancers1
2RecruitingTreatmentColon Carcinoma1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentLymphangioleiomyomatosis (LAM)1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentOsteoarthritis of the Knees1
2RecruitingTreatmentThyroid Eye Disease1
2RecruitingTreatmentTonsillectomy1
2RecruitingTreatmentTumors, Solid1
2TerminatedNot AvailableUterine Cancers1
2TerminatedPreventionCancer, Breast1
2TerminatedPreventionPancreas Neoplasms1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Malignant Neoplasm of Prostate1
2TerminatedTreatmentBrain and Central Nervous System Tumors1
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentColorectal Cancers / Familial Adenomatous Polyposis (FAP)1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentHead and Neck Carcinoma / Lung Cancers1
2TerminatedTreatmentLaryngeal Papilloma1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentMalignant Neoplasm of Prostate1
2TerminatedTreatmentMalignant Neoplasm of Prostate / Metastatic Cancers1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2TerminatedTreatmentOsteoarthritis of the Knees1
2TerminatedTreatmentOvarian Carcinoma1
2TerminatedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentRheumatoid Arthritis1
2Unknown StatusPreventionHead and Neck Carcinoma1
2Unknown StatusSupportive CareOsteoarthritis of the Knees1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors2
2Unknown StatusTreatmentColorectal Cancers1
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentLung Cancers2
2Unknown StatusTreatmentMalignant Neoplasm of Prostate2
2WithdrawnPreventionNon-Melanomatous Skin Cancer1
2WithdrawnTreatmentHigh-Grade Squamous Intraepithelial Lesions / Stage 0 Cervical Cancer1
2WithdrawnTreatmentPreEclampsia1
2, 3CompletedPreventionDuodenal Neoplasms / Duodenal Polyps / Familial Adenomatous Polyposis (FAP)1
2, 3CompletedPreventionRecurrent Bladder Cancer1
2, 3CompletedTreatmentMalignant Neoplasm of Prostate1
2, 3RecruitingTreatmentMalignant Neoplasm of Prostate1
2, 3TerminatedTreatmentOral Cavity Cancer1
2, 3WithdrawnPreventionPrecancerous Conditions1
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentColorectal Cancers1
3Active Not RecruitingTreatmentLung Cancers1
3CompletedPreventionAlzheimer's Disease (AD)1
3CompletedPreventionMalignant Neoplasm of Colon / Rectal Carcinoma1
3CompletedPreventionPrevention / Smoking1
3CompletedSupportive CareCelebrex / Pelubiprofen / Rheumatoid Arthritis1
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentAnkylosing Spondylitis (AS)2
3CompletedTreatmentAnterior Cruciate Ligament Injury1
3CompletedTreatmentArthritis, Juvenile Rheumatoid1
3CompletedTreatmentArthritis / Bleeding Ulcers1
3CompletedTreatmentArthritis / Cardiovascular Disease (CVD) / Cerebrovascular Disorders1
3CompletedTreatmentArthritis / Gastric Ulcer (GU)1
3CompletedTreatmentColorectal Adenomas1
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentHypertensive1
3CompletedTreatmentLow Back Pain (LBP)2
3CompletedTreatmentMacular Degeneration1
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3CompletedTreatmentOsteoarthritis of the Knees6
3CompletedTreatmentOther Acute Postoperative Pain2
3CompletedTreatmentPain1
3CompletedTreatmentPain / Synovitis of osteoarthritis1
3CompletedTreatmentPeptic Ulcers / Synovitis of osteoarthritis1
3CompletedTreatmentPharyngitis1
3CompletedTreatmentPost Operative Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentSynovitis of osteoarthritis11
3Not Yet RecruitingTreatmentBipolar Disorder (BD) / Postpartum Depression1
3RecruitingPreventionHysteroscopy2
3RecruitingTreatmentBipolar Disorder (BD) / Depression, Bipolar / Depressive State / Moods Disorders1
3RecruitingTreatmentHypertensive1
3RecruitingTreatmentInfluenza, Human1
3RecruitingTreatmentLiver Cancer / Postoperative pain1
3RecruitingTreatmentLow Back Pain (LBP)1
3RecruitingTreatmentNasopharyngeal Carcinoma1
3RecruitingTreatmentOsteoarthritis of the Knees / Synovitis of osteoarthritis1
3RecruitingTreatmentPain, Acute2
3SuspendedTreatmentMemory Disorders1
3SuspendedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3TerminatedPreventionAdenomatous Polyposis Coli1
3TerminatedPreventionColorectal Cancers1
3TerminatedPreventionSynovitis of osteoarthritis1
3TerminatedSupportive CareCancer, Breast / Colorectal Cancers / Pain1
3Unknown StatusNot AvailableMalignant Neoplasm of Pancreas1
3Unknown StatusTreatmentColon Neoplasms1
3Unknown StatusTreatmentHead and Neck Carcinoma1
3Unknown StatusTreatmentLocalized Primary Osteoarthritis of Hip / Localized Primary Osteoarthritis of Knee1
3Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
4Active Not RecruitingTreatmentAnkylosing Spondylitis (AS) / Inflammatory Reaction1
4CompletedNot AvailableCelecoxib / Function / Minimally Invasive Total Knee Arthroplasty / Pain Management1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedBasic ScienceHypertensive1
4CompletedBasic ScienceIschaemic Heart Diseases / Synovitis of osteoarthritis1
4CompletedPreventionArthroscopy2
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionPeptic Ulcers1
4CompletedPreventionRheumatoid Arthritis / Synovitis of osteoarthritis1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentAnkle Sprains1
4CompletedTreatmentArthritis, Juvenile Rheumatoid1
4CompletedTreatmentBack Pain1
4CompletedTreatmentBack Pain Lower Back1
4CompletedTreatmentBowel Diseases, Inflammatory1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCyclooxygenase 2 Inhibitors / Postoperative pain / Thyroidectomy1
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHepatocellular,Carcinoma1
4CompletedTreatmentHypertension and Coronary Artery Disease1
4CompletedTreatmentInflammatory Reaction / Pain1
4CompletedTreatmentLow Back Pain (LBP)1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentOsteoarthritis of the Knees7
4CompletedTreatmentOsteoarthritis of the Knees / Osteoarthritis, Hip1
4CompletedTreatmentOsteoarthritis, Hip1
4CompletedTreatmentPostoperative Pain Management / Total Knee Arthroplasty (TKA)1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRheumatoid Arthritis / Synovitis of osteoarthritis1
4CompletedTreatmentRotator Cuff Syndrome1
4CompletedTreatmentSynovitis of osteoarthritis2
4Enrolling by InvitationTreatmentBile Duct Carcinoma / Malignant Neoplasm of Pancreas1
4Not Yet RecruitingPreventionPain1
4Not Yet RecruitingTreatmentAnkylosing Spondylitis (AS)1
4Not Yet RecruitingTreatmentPain Management1
4Not Yet RecruitingTreatmentPharmacokinetics of Celecoxib in Children1
4Not Yet RecruitingTreatmentPostoperative pain1
4RecruitingPreventionPostoperative pain1
4RecruitingTreatmentAnkylosing Spondylitis (AS)1
4RecruitingTreatmentLigament Injury1
4RecruitingTreatmentOsteoarthritis Hand1
4RecruitingTreatmentRheumatoid Arthritis1
4RecruitingTreatmentSynovitis of osteoarthritis1
4TerminatedNot AvailableFamilial Adenomatous Polyposis (FAP)1
4TerminatedTreatmentChronic Low Back Pain (CLBP)1
4TerminatedTreatmentChronic Low Back Pain With a Neuropathic Component1
4TerminatedTreatmentCrohn's Disease (CD)1
4TerminatedTreatmentOsteoarthritis of the Knees1
4TerminatedTreatmentPain1
4TerminatedTreatmentPain / Synovitis of osteoarthritis1
4TerminatedTreatmentUterine Artery Embolization / Uterine Leiomyomas1
4Unknown StatusDiagnosticHealthy Volunteers1
4Unknown StatusTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Coronary Artery Restenosis1
4Unknown StatusTreatmentOsteoarthritis of the Knees1
4Unknown StatusTreatmentPain1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
4WithdrawnTreatmentPost Operative Pain Control1
4WithdrawnTreatmentUreteral Calculus1
Not AvailableActive Not RecruitingTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableActive Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS)1
Not AvailableCompletedNot AvailablePatients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain1
Not AvailableCompletedNot AvailableSynovitis of osteoarthritis1
Not AvailableCompletedDiagnosticGonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P) / Menstrual Cycles (Total Length, Bleeding Days) / Ovulation (Follicular Rupture Yes/no)1
Not AvailableCompletedDiagnosticLuteal Development / Ovulation1
Not AvailableCompletedPreventionAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedScreeningHealthy Volunteers1
Not AvailableCompletedTreatmentAntiphospholipid Antibody Syndrome1
Not AvailableCompletedTreatmentHip Labral Tears1
Not AvailableCompletedTreatmentIntracerebral Hemorrhage1
Not AvailableCompletedTreatmentLung Cancers1
Not AvailableCompletedTreatmentOsteoarthritis of the Knees1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedTreatmentSquamous Cell Carcinoma (SCC)1
Not AvailableNot Yet RecruitingPreventionPrevention of Post Operative Ileus1
Not AvailableNot Yet RecruitingTreatmentStiffness Following Total Knee Arthroplasty1
Not AvailableNot Yet RecruitingTreatmentTreatment Outcomes1
Not AvailableRecruitingPreventionOssification, Heterotopic1
Not AvailableTerminatedNot AvailableArthritis, Juvenile Rheumatoid1
Not AvailableTerminatedNot AvailableSynovitis of osteoarthritis1
Not AvailableTerminatedTreatmentColorectal Cancers1
Not AvailableTerminatedTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
Not AvailableTerminatedTreatmentDiabetic Nephropathies1
Not AvailableTerminatedTreatmentPain1
Not AvailableUnknown StatusNot AvailableHip Fractures1
Not AvailableUnknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Blunt Chest Trauma1
Not AvailableUnknown StatusTreatmentHealthy Volunteers1
Not AvailableUnknown StatusTreatmentPostoperative pain2
Not AvailableWithdrawnPreventionBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Cancer, Ovarian1
Not AvailableWithdrawnSupportive CareCachexia / Cancer, Ovarian / Malignant Lymphomas / Melanoma (Skin) / Pain / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableWithdrawnTreatmentBladder Cancers1
Pharmacoeconomics
Manufacturers
  • Gd searle llc
Packagers
Dosage forms
FormRouteStrength
KitOral; Topical
CapsuleOral100 mg
CapsuleOral200 mg
CapsuleOral100 mg/1
CapsuleOral200 mg/1
CapsuleOral400 mg/1
CapsuleOral50 mg/1
CapsuleOral400 mg
Prices
Unit descriptionCostUnit
Celebrex 400 mg capsule6.78USD capsule
Celebrex 200 mg capsule4.52USD capsule
Celebrex 100 mg capsule2.75USD capsule
Celebrex 50 mg capsule1.26USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2177576 No1999-10-262014-11-14Canada
CA2267186 No2002-05-142017-10-14Canada
US5466823 No1993-11-302013-11-30Us
US5972986 No1998-04-142018-04-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)158 °CPhysProp
water solubilityVery low water solubility (3.3 mg/L)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00503 mg/mLALOGPS
logP3.99ALOGPS
logP4.01ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)-0.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.98 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.23 m3·mol-1ChemAxon
Polarizability35.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.9287
P-glycoprotein inhibitor INon-inhibitor0.8619
P-glycoprotein inhibitor IINon-inhibitor0.792
Renal organic cation transporterNon-inhibitor0.8582
CYP450 2C9 substrateNon-substrate0.6237
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5751
CYP450 1A2 substrateInhibitor0.7805
CYP450 2C9 inhibitorInhibitor0.6172
CYP450 2D6 inhibitorNon-inhibitor0.8594
CYP450 2C19 inhibitorInhibitor0.7169
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7392
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7905
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9856
hERG inhibition (predictor II)Non-inhibitor0.8419
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-001i-0129000000-a967b7f9e88a461e3db4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QFT , positivesplash10-001i-0029000000-13ff69b3abd31dde6baeView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassAzoles
Direct ParentPhenylpyrazoles
Alternative ParentsBenzenesulfonamides / Benzenesulfonyl compounds / Toluenes / Organosulfonamides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organofluorides
SubstituentsPhenylpyrazole / Benzenesulfonamide / Benzenesulfonyl group / Toluene / Monocyclic benzene moiety / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsorganofluorine compound, pyrazoles, sulfonamide (CHEBI:41423 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Uniprot Name:
Prostaglandin G/H synthase 2
Molecular Weight:
68995.625 Da
References
  1. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002 Jun;122(7):1913-23. [PubMed:12055598 ]
  2. Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. [PubMed:12086292 ]
  3. Reddy BS, Rao CV: Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21(2):155-64. [PubMed:12086402 ]
  4. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. [PubMed:12093311 ]
  5. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 2002 Oct 8;184(1):7-12. [PubMed:12104042 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein serine/threonine kinase activity
Specific Function:
Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1), p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3), cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), ser...
Gene Name:
PDPK1
Uniprot ID:
O15530
Uniprot Name:
3-phosphoinositide-dependent protein kinase 1
Molecular Weight:
63151.305 Da
References
  1. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004 Feb 15;64(4):1444-51. [PubMed:14973075 ]
  2. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. [PubMed:15205346 ]
  3. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005 Oct 15;391(Pt 2):441-8. [PubMed:16060857 ]
  4. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg. 2006 Feb;10(2):207-14. [PubMed:16455452 ]
  5. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3. [PubMed:16887935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Uniprot Name:
Carbonic anhydrase 2
Molecular Weight:
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide.
Gene Name:
CA3
Uniprot ID:
P07451
Uniprot Name:
Carbonic anhydrase 3
Molecular Weight:
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225-42. [PubMed:10749518 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
  6. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K: Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003 Aug;74(2):130-7. [PubMed:12891223 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Uniprot Name:
Alpha-1-acid glycoprotein 1
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Uniprot Name:
Multidrug resistance-associated protein 4
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:49